The Effect of Sildenafil on Intrauterine Growth Restriction (IUGR) of Fetus with Gestational Age above 28 Weeks and Neonatal Outcomes

Effect of Sildenafil on Intrauterine Growth Restriction (IUGR) of Fetus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200526006

Enrollment

Unknown

Registered

2020-05-26

Start date

2019-05-25

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine growth restriction (IUGR) Sildenafil Citrate Fetus Gestational age Infant&#44

Interventions

The sildenafil group received 25 mg of oral sildenafil,The control group received a drug with the same shape and weight daily (Placebo).

Experimental Drug,Placebo Comparator Drug

Sildenafil,Placebo

Eligibility

Sex/Gender

All

Age

19 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria were 1) pregnancy with gestational age above 28 weeks. 2) Occurrence of IUGR in fetal weight below 10% percentiles and AC less than 3%, and 3) Ultrasound indicating fetal vascular Doppler disorder.

Exclusion criteria

Exclusion criteria: Exclusion criteria were 1) Patients with unknown gestational age, 2) Having specific fetal anomalies, 3) Taking vasodilator drugs, 4) Multiple pregnancy, and 5) Smoking or alcohol use drugs pregnancy

Design outcomes

Primary

Measure	Time frame
Placental function 2 (Before and after intervention) Doppler ultrasound	—

Secondary

Measure	Time frame
Intrauterine Growth Restriction (IUGR) 2 (Before and after intervention) Doppler Ultrasound	—

Countries

Iran

Contacts

Public ContactAkbarabadi Teaching Hospital Akbarabadi Teaching Hospital

Department of Obstetrics and Gynecology, Iran University of Medical Sciences, Akbarabadi Teaching Ho

fahimehkarimi554@gmail.com+98 21 22 43 97 70

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026